Eli Lilly Sues Glenmark Over Cancer Drug ANDA

Law360, Los Angeles (January 23, 2014, 3:46 PM EST) -- Eli Lilly & Co. sued Glenmark Generics Inc. USA on Thursday in Indiana federal court, alleging the company's proposed generic version of its blockbuster cancer treatment drug Alimta infringes one of its patents.

Lilly claims that Glenmark's proposed generic Alimta infringes its U.S. Patent Number 7,772,209, which covers a method of administering pemetrexed disodium — Alimta's active ingredient — along with folic acid and vitamin B12.

Thursday's suit was the latest in a string of actions Lilly has filed to enforce the '209 patent since it...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.